Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Viewpoint
Nature Reviews Clinical Oncology 3, 2–3 (1 January 2006) | doi:10.1038/ncponc0384
Clinical management of BRCA1 and BRCA2 mutation carriers
&
Abstract
Women with BRCA1/2 mutations have a higher risk of breast and ovarian cancer than the general population. The authors outline current evidence for strategies to reduce the risks of cancer development in these women, and discuss future research directions.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
